BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Strs Ohio

Strs Ohio decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 78.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,185 shares of the biotechnology company’s stock after selling 145,600 shares during the quarter. Strs Ohio’s holdings in BioMarin Pharmaceutical were worth $3,527,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Arden Trust Co purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $597,000. Commerzbank Aktiengesellschaft FI increased its position in shares of BioMarin Pharmaceutical by 12.5% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,276 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 586 shares in the last quarter. Landsberg Bennett & Dubbaneh LLC purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $279,000. Rhenman & Partners Asset Management AB increased its position in shares of BioMarin Pharmaceutical by 21.5% during the second quarter. Rhenman & Partners Asset Management AB now owns 281,349 shares of the biotechnology company’s stock worth $24,098,000 after purchasing an additional 49,800 shares in the last quarter. Finally, Kistler Tiffany Companies LLC increased its position in shares of BioMarin Pharmaceutical by 627.9% during the second quarter. Kistler Tiffany Companies LLC now owns 1,980 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 1,708 shares in the last quarter. 98.38% of the stock is owned by hedge funds and other institutional investors.

In other news, Director V Bryan Lawlis sold 3,750 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $81.08, for a total value of $304,050.00. Following the transaction, the director now owns 27,340 shares of the company’s stock, valued at approximately $2,216,727.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Several brokerages recently commented on BMRN. Cantor Fitzgerald reiterated a “buy” rating and set a $131.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, April 26th. TheStreet cut BioMarin Pharmaceutical from a “c-” rating to a “d+” rating in a research report on Tuesday, May 7th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $133.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, August 5th. Wedbush reiterated an “outperform” rating and set a $128.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, July 10th. Finally, BidaskClub cut BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Buy” and an average price target of $115.60.

NASDAQ BMRN opened at $76.99 on Friday. The stock’s fifty day moving average is $81.99. The firm has a market capitalization of $13.80 billion, a price-to-earnings ratio of -233.30 and a beta of 1.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.11 and a quick ratio of 2.76. BioMarin Pharmaceutical Inc. has a fifty-two week low of $74.83 and a fifty-two week high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). The company had revenue of $388.00 million for the quarter, compared to analyst estimates of $415.03 million. BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The business’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period last year, the firm posted ($0.09) EPS. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post -0.03 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Article: What is meant by holder of record?

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.